High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Genome engineering of T lymphocytes, the main effectors of antitumor adaptive immune responses, has the potential to uncover unique insights into their functions and enable the development of next-generation adoptive T cell therapies. Viral gene delivery into T cells, which is currently used to generate CAR T cells, has limitations in regard to targeting precision, cargo flexibility, and reagent production. Nonviral methods for effective CRISPR/Cas9-mediated gene knock-out in primary human T cells have been developed, but complementary techniques for nonviral gene knock-in can be cumbersome and inefficient. Here, we report a convenient and scalable nonviral method that allows precise gene edits and transgene integration in primary human T cells, using plasmid donor DNA template and Cas9-RNP. This method is highly efficient for single and multiplex gene manipulation, without compromising T cell function, and is thus valuable for use in basic and translational research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous studies showing that overly high plasmid concentrations can lead to cellular toxicity, reduced transfection efficiency, or activation of cellular stress responses to impair HDR efficiency [20,25].”
From Rapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9 (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · cited 1×
“Gene set enrichment analysis (GSEA) was performed using R Bioconductor package enrichplot (Yu, 2021) andmsigdbr (Subramanian et al., 2005; Liberzon et al., 2015).”
MethodOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 2×
“This approach was used, for instance, to insert a CAR construct into the T cell receptor α constant (TRAC) region locus, which placed the CAR under the control of the endogenous TCR promotor, thus improving its performance (Eyquem et al., 2017).”
MethodLi, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715 · cited 1×
“Homology-directed repair (HDR) of double-strand DNA breaks introduced by targeted gene editing methods, such as transcription activator–like effector nucleases, zinc finger nucleases, or CRISPR/Cas9, can be used to make precise changes to a genomic sequence, including the insertion of long stretches of DNA at a define…”
BackgroundCRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · cited 2×
“As we and others have demonstrated, chromosomal translocations are a predicted byproduct of multiplex gene perturbation (Stadtmauer et al., 2020).”
BackgroundResultA bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., Sell, B. R., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,289 · cited 1×
“, 2005) fused with the fluorescent protein mNeonGreen (mNG; Shaner et al., 2013).”
Method
Cited by
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2023) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 285
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 154
“Process improvements, including single-stranded DNA donor templates 62,71 , nanoplasmids 72 , intranuclear template shuttling 73 , Cas9 RNP stabilization 73 and small molecule cocktails 71 , may increase editing rates.”
BackgroundLei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 175
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“Targeted insertion of a transgene into the host genome can be mediated by HDR following double-strand break introduced by CRISPR at a specific genomic site (Hayashi et al., 2020; Nitzahn et al., 2021; Oh et al., 2022).”
BackgroundLiu, X., Cao, Z., Wang, W., Zou, C., Wang, Y., Pan, L., Jia, B., Zhang, K., Zhang, W., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12857 · Cited by 132
Non-viral chimeric antigen receptor (CAR) T cells going viral
Balke‐Want, H., Keerthi, V., Cadiñanos-Garai, A., Fowler, C., Gkitsas-Long, N., Brown, A. K., Tunuguntla, R. H., Abou‐El‐Enein, M., & Feldman, S. A. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100375 · Cited by 90
“The use of linearized DNA or plasmid DNA as a template for target insertion, however, may address some of the limitations of AAV6based CRISPR/Cas9 knock-in, but this approach has been associated with high cell toxicity and low knock-in efficiencies.(21,22,48) A study evaluating CRISPR/Cas9-mediated knock-in of an anti…”
BackgroundInfluentialA highly efficient transgene knock-in technology in clinically relevant cell types
Allen, A. G., Khan, S., Margulies, C. M., Viswanathan, R., Lele, S. S., Blaha, L. C., Scott, S. N., Izzo, K. M., Gerew, A., Pattali, R. K., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01779-8 · Cited by 77
“Non-viral DNA templates have previously been shown to be more toxic and less efficient at KI than AAV6, thus limiting their potential 31–33 , although recent progress has led to efficiencies of more than 50% in T cells 34 .”
Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
Qasim, W. (2022) · Blood · doi:10.1182/blood.2022016204 · Cited by 73
Engineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 73
Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65
“S3) which may be reduced by careful titration of the dsDNA template, small-molecule drugs to temporarily prevent DNA sensing [41] or the use of nanoplasmids [59], circularized ssDNA [60], or linear ssDNA [61] as donor templates.”
IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control
Bréart, B., Williams, K., Krimm, S., Wong, T., Kayser, B. D., Wang, L., Cheng, E., Tleugabulova, M. C., Bouziat, R., Lu, T., et al. (2025) · Nature · doi:10.1038/s41586-024-08510-w · Cited by 64
“T cells were cultured for 36–48 h before electroporation and co-transfection with sgTRAC-and sgTRBC-containing Cas9–RNPs, together with 4 μg of nanoplasmid encoding CMV A2/pp65 495–503 -specific TCR6-2 as described previously 77 .”
Self-citationBalke‐Want, H., Keerthi, V., Gkitsas-Long, N., Mancini, A. G., Kurgan, G., Fowler, C., Xu, P., Liu, X., Asano, K., Patel, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01799-7 · Cited by 53
“Furthermore, a recent report indicates nanoplasmid DNA to be more efficient in transgene delivery than dsDNA [47].”
BackgroundResultImproving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors
Williams, J. A., & Paez, P. A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.04.003 · Cited by 39
“This figure was adapted fromOh et al.(81) “High-efficiency nonviral CRISPR/cas9-mediated gene editing of human T cells using plasmid donor DNA.”
BackgroundMethodInfluentialCappabianca, D., Pham, D. L., Forsberg, M. H., Bugel, M., Tommasi, A. M., Lauer, A. C., Vidugirienė, J., Hrdlicka, B., McHale, A., Sodji, Q. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101249 · Cited by 38
Antigen specificity of clonally enriched CD8+ T cells in multiple sclerosis
Hayashi, F., Mittl, K., Dandekar, R., Gerdts, J., Hassan, E., Schubert, R. D., Oshiro, L., Loudermilk, R. P., Greenfield, A. L., Augusto, D. G., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02412-3 · Cited by 42
Shakirova, A. I., Karpov, T. E., Komarova, Y., & Lepik, K. V. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1068637 · Cited by 34
“Reducing the size of the backbone vector reliably lowers the toxicity of plasmid DNA (Oh et al., 2022), probably because it reduces the overall amount of DNA introduced into the cell at an equal number of molecules of the embedded sequence.”
BackgroundMethodReichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 33
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
Yao, Z., Zeng, Y., Liu, C., Jin, H., Wang, H., Zhang, Y., Ding, C., Chen, G., & Wu, D. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03195-5 · Cited by 34
“…is lower than viral transduction, various improvement meth-ods, such as single-stranded DNA (ssDNA) homology-directed repair (HDR) templates [84], nanoplasmid [85], stabilization of Cas9 RNP sand enhancement of template nuclear shuttling [86], have been designed to improve editing efficiency.”
BackgroundCoengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 30
Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing
Rostami, N., Gomari, M. M., Choupani, E., Abkhiz, S., Fadaie, M., Eslami, S. S., Mahmoudi, Z., Zhang, Y., Puri, M., Monfared, F. N., et al. (2024) · Small Science · doi:10.1002/smsc.202400192 · Cited by 31
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity
Zuo, Y.-H., Vohwinkel, D. J., Dong, B., McDowell, J. R., Guzman, B. V., Pandian, T. S. M., Chattopadhyay, S., McGray, A. R., Olejniczak, S. H., Ohm, J. E., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.11.007 · Cited by 26
SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci
Chang, C. R., Vykunta, V. S., Lee, J. H. J., Li, L., Kochendoerfer, C., Muldoon, J. J., Wang, C. H., Mazumder, T., Sun, Y., Goodman, D. B., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02531-6 · Cited by 23
Sytsma, B. J., Allain, V., Bourke, S., Faizee, F., Fathi, M., Ferreira, L. M. R., Brewer, W. J., Li, L., Pan, F. L., Rothrock, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89070-5 · Cited by 21
“In light of these advances, a series of seminal papers have been published which demonstrate the utility of CRISPR/Cas9 as a tool for adoptive T-cell engineering 19,16,15,20 .”
Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
“Dedicated protocols for electroporation of T cells 30,74 and HSPCs 21 are available, and peptide-mediated RNP delivery has been extensively compared with electroporation in previous studies 15,16 .”
Kruglova, N. A., & Shepelev, M. V. (2024) · Biomedicines · doi:10.3390/biomedicines12010119 · Cited by 18
“Roth et al. showed that the highest levels of knock-in can be achieved by first mixing RNP and donor DNA and then adding them to cells.”
BackgroundMethodResultInfluentialBiomembrane-wrapped gene delivery nanoparticles for cancer therapy
Li, J., Zeng, H., Li, L., Song, M. H., & Dong, M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1211753 · Cited by 17
CRISPR/Cas-Based Gene Editing Tools for Large DNA Fragment Integration
Yang, S., Hu, G., Wang, J., & Song, J. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00632 · Cited by 19
Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT
Tommasi, A. M., Cappabianca, D., Bugel, M., Gimse, K., Lund-Peterson, K., Shrestha, H., Arutyunov, D., Williams, J. A., Police, S. R., Indurthi, V. S. K., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101437 · Cited by 17
“23 In addition, having minimal bacterial back-bone reduces transgene silencing after genomic insertion.”
Clinical development of allogeneic chimeric antigen receptor αβ-T cells
Georgiadis, C., Preece, R., & Qasim, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.040 · Cited by 17
“77,80,81 A similar strategy has used CRISPR-Cas12a and chimeric RNA-DNA guides in combination with AAV template delivery CAR and non-polymor-phic HLA.”
Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer
Sueangoen, N., & Prasongtanakij, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01820-x · Cited by 16
“- Specific gene editing - High efficiency - Safe harbor integration - Off-target effects - Electroporation toxicity [69, 286] they have proven to be effective in the generation of CAR T cells [36].”
Manufacturing next-generation regulatory T-cell therapies
MacDonald, K. N., Salim, K., & Levings, M. K. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102822 · Cited by 17
Applications of CRISPR technology in cellular immunotherapy
Zhou, X., Renauer, P. A., Zhou, L., Fang, S., & Chen, S. (2023) · Immunological Reviews · doi:10.1111/imr.13241 · Cited by 15
“78 This approach using plasmid DNA, which is amenable to large-scale and quality manufacturing practices, provides an alternative way to manufacture genetic engineered cellular products for clinic usage.”
BackgroundMethodNitulescu, A.-M., Du, W., Glaser, V., Kath, J., Aird, E. J., Cullot, G., Greensmith, R., Mikkelsen, N. S., Stein, M., Bak, R. O., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102568 · Cited by 12
“The most commonly used non-viral template formats include plasmids, 17–22 linear double-stranded DNA (dsDNA), 5,23–29 and single-stranded DNA (ssDNA).”
Induction of immune tolerance in NMOSD and MOGAD
Correale, J. D., & Contentti, E. C. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251357393 · Cited by 12
Precise Gene Knock‐In Tools with Minimized Risk of DSBs: A Trend for Gene Manipulation
Liu, Y. H., Kong, J., Liu, G., Li, Z., & Xiao, Y. (2024) · Advanced Science · doi:10.1002/advs.202401797 · Cited by 13
Genome editing approaches for universal chimeric antigen receptor T cells
Mishra, A. K., & Qasim, W. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100149 · Cited by 10
Allogeneic CAR-T cells for cancer immunotherapy
Chen, X., Gao, Y., & Zhang, Y. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2408048 · Cited by 11
Molecular determinants of cross-strain influenza A virus recognition by αβ T cell receptors
Quiñones‐Parra, S. M., Gras, S., Nguyen, T. H. O., Farenc, C., Szeto, C. W., Rowntree, L. C., Chaurasia, P., Sant, S. A., Boon, A. C. M., Jayasinghe, D., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adn3805 · Cited by 9
Application of CRISPR-Cas9 in microbial cell factories
Yang, J., Song, J., Feng, Z., & Ma, Y. (2025) · Biotechnology Letters · doi:10.1007/s10529-025-03592-6 · Cited by 9
“The spacers are then translated into CRISPR RNAs (crRNAs), which enable cells to fend against invasion when combined with trans-activating crR-NAs (tracrRNAs) (Liao and Beisel 2021; Oh et al. 2022) and the endonuclease Cas9.”
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 8
“146 Furthermore, this strategy allows enhanced control over the duration of component presence in cells while minimizing off-target effects and toxicity.”
Liu, C. J. S., Wang, S.-B., Su, P.-Y., Hsieh, Y.-P., & Wang, H.-Y. A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115851 · Cited by 7
Balke‐Want, H., Keerthi, V., Arenas, M. D. C., Chen, Y., Malipatlolla, M. B., Klysz, D. D., Xu, P., Ho, K., Asano, K., Stahl, D. J., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102549 · Cited by 7
Jiang, K., Jin, Y., Luo, P., Wang, X., Zhang, Y., Shi, T., Chen, J., Song, P., & Lü, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135220 · Cited by 6
McAuliffe, J., Panetti, S., Steffke, E. E., Wicki, A., Almeida, V. P., Noblecourt, L., Hu, Y., Guo, S. Y. W., Lesenfants, J., Ramirez-Valdez, R. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008998 · Cited by 6
Wang, L., Liang, Z., Li, D., Chen, Y., Ma, G., & Liang, Y. (2023) · Biomedical Materials · doi:10.1088/1748-605x/ace39d · Cited by 6
“To overcome the low transfection efficiency and low expression of the transgenes, efficient and targeted vectors with low systemic toxicity should be developed for delivering plasmids into target cells [73, 74].”
Gong, J. D., Samarkhazan, H. S., Siavashi, M., Servatian, N., & Pirsavabi, F. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11235-2 · Cited by 5
Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters
Sanchez‐Pupo, R. E., Kelly, J. J., Shalaby, N., Xia, Y., Martínez‐Santiesteban, F., Lau, J., Verriet, I. E., Fox, M. S., Hicks, J. W., Thiessen, J. D., et al. (2026) · Theranostics · doi:10.7150/thno.119013 · Cited by 5
“These efficiencies are comparable to recent reports using Cas9 [68], Cas12a [69], non-viral donors [70], and advanced enrichment and base-editing platforms to enable multilocus CRISPR edits at TRAC and B2M loci [71,72].”
Preliminary study on mitochondrial DNA analysis from different sports items
Noor, S., Akhtar, S., Khan, M. F., Rehman, R. A., Salman, M., Nazir, S., Rakha, A., Ullah, I., & Munawar, A. (2024) · Forensic Science International · doi:10.1016/j.forsciint.2024.112077 · Cited by 5
Analytical and Functional Characterization of Plasmid DNA Topological Forms and Multimers
Nguyen, D. N., Ko, P., Roper, B., Console, G., Gao, Y., Shaw, D., Yu, C., Yehl, P., Zhang, K., & Goyon, A. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02150 · Cited by 5
Self-citationEfficient bi-allelic tagging in human induced pluripotent stem cells using CRISPR
Ren, X., Takagi, M. A., & Shen, Y. (2023) · STAR Protocols · doi:10.1016/j.xpro.2023.102084 · Cited by 5
“The knock-in efficiency positively correlates with the length of homology arms.(8,9) Larger vectors lead to decreased transfection efficiency and cell viability.”
BackgroundMoshref, M., Lo, J. H.-H., McKay, A. S., Camperi, J., Schroer, J., Ueno, N., Wang, S., Gulati, S., Tarighat, S. S., Durinck, S., et al. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1417070 · Cited by 5
Self-citationEfficient and precise programmable DNA knock-in without double-strand breaks
Gao, Y., Ma, Y., Yu, K., Liu, Y., Gu, B., Tang, H., Yan, W. L., Yang, S. M., Su, J., Wang, X., et al. (2026) · Nature · doi:10.1038/s41586-026-10819-7 · Cited by 4
“Recent studies have further improved Cas9-based integration efficiency and viability using optimized donor formats, such as circular single-stranded DNA (cssDNA), single-stranded DNA (ssDNA) and nanoplasmids 18,35,52 , but the risks inherent to DSBs remain.”
Quezada‐Ramírez, M. A., Loncar, S., Campbell, M. A., Parsi, K. M., Gifford, R. J., & Kotin, R. M. (2025) · iScience · doi:10.1016/j.isci.2025.113910 · Cited by 4
“…insertion in human CD34 + HSPCs Gene targeting into HSPCs has been reported using plasmids or linear double-stranded DNA (dsDNA) carrying homology arms to mediate the homologous recombination (HR) 21,48 or flanked with gRNA recognition sites for an homology-independent targeted integration (HITI).”
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy
Camperi, J., Devarajan, S., McKay, A. S., Tarighat, S. S., Chen, D., & Hu, Z. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113491 · Cited by 3
Self-citationKassing, I., Kath, J., Nitulescu, A.-M., Glaser, V., Hartmann, L. M., Pu, Y., Huth, L., Kārkliņš, R., Shaji, S. M., Ringel, A. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.10.675267 · Cited by 3
Ultra-large targeted DNA integrations in primary human cellsPreprint
Kernick, C., Chow, L., Alejandro, M., Li, K., Foisey, M. G., Yang, X., Hilburger, C. E., Lu, J., Wu, L., McClellan, A. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.09.717505 · Cited by 3
Cruz-Chuh, J. D., Siegismund, D., Moffat, J., Heyse, S., Kozak, K. R., & Steigele, S. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100297 · Cited by 2
My, B., Lia, A., Rizzo, L., Maiorano, G., Galeone, A., Palamà, I. E., & Gigli, G. (2026) · iScience · doi:10.1016/j.isci.2026.115422 · Cited by 2
Džafo, E., Hafezi, M., Attianese, G. M. P. G., Reichenbach, P., Grillet, S., Garcia, H., Cribioli, E., Voize, C., Tissot-Renaud, S., de Silly, R. V., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.02.001 · Cited by 2
Prasetia, I. G., Kurniati, N. F., Riani, C., & Mudhakir, D. (2025) · Narra J · doi:10.52225/narra.v5i1.2217 · Cited by 3
“Electrostatic interactions between charged components and the process of reorganization of nanoparticle structures play an important role in these conditions [29,82,83].”
InfluentialRapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9
Yang, J., Guo, F., Chin, H. S., Chen, G. B., Zhang, Z., Williams, L., Kueh, A. J., Chow, P. K. H., Herold, M. J., & Fu, N. Y. (2025) · Cells · doi:10.3390/cells14151165 · Cited by 1
“To integrate a fluorescent reporter into the genome by CRISPR-Cas9 genome editing, we first tested a dual-plasmid system, as commonly employed in previous studies [16–20].”
Sato, Y., Hanawa, Y., & Tsubota, A. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.10.002 · Cited by 2
Kim, J., & Lee, H. (2025) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2025.35.1.1 · Cited by 1
Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.029 · Cited by 2
Natsagdorj, M., Hara, H., Iida, K., Kashiwakura, Y., Baatartsogt, N., Ganzorig, E., Canarutto, D., Pinho, S., Luigi, N., Ohmori, T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1016/j.exphem.2025.105150 · Cited by 1
Kim, J.-H., Cho, H. J., & Lee, H. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154003 · Cited by 1
Plasmid‐Based Donor Templates for Nonviral CRISPR/Cas9‐Mediated Gene Knock‐In in Human T Cells
Senger, K., Akhmetzyanova, I., Haley, B., Rutz, S., & Oh, S. A. (2022) · Current Protocols · doi:10.1002/cpz1.538 · Cited by 1
“Although the protocol described here has been demonstrated to work well for knock-ins across multiple loci (Oh et al., 2022), targeting novel genomic sites may require additional optimization of the knock-in process.”
BackgroundSelf-citationWeijler, A. M., & Wekerle, T. (2023) · Transplantation · doi:10.1097/tp.0000000000004814 · Cited by 1
Golubev, D. S., Komkov, D., Shepelev, M. V., Mazurov, D. V., & Kruglova, N. A. (2023) · Doklady Biological Sciences · doi:10.1134/s0012496623700862 · Cited by 1
Shepelev, M. V., Komkov, D., Golubev, D. S., Borovikova, S. E., Mazurov, D. V., & Kruglova, N. A. (2024) · Molecular Biology · doi:10.1134/s0026893324700250 · Cited by 1
“An increase in knock-in by factors of 2–4 [17, 19] or 1.5 [20, 22] has been reported as well as lack of any effect [21].”
InfluentialShepelev, M. V., Komkov, D., Golubev, D. S., Borovikova, S. E., Mazurov, D. V., & Kruglova, N. A. (2024) · Molecular Biology · doi:10.31857/s0026898424040058 · Cited by 1
TESOGENASE, An Engineered Nuclease Editor for Enhanced Targeted Genome IntegrationPreprint
Nam, H., Xie, K., Majumdar, I., Yang, S., Starzyk, J., Lee, D., Shan, R., Li, J., & Wu, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.28.553855 · Cited by 1
“These nucleic acid donor templates have enabled relatively efficient gene targeting in various primary cells, including T cells and natural killer cells (Huang et al., 2021; Miura et al., 2015; Oh et al., 2022; Roth et al., 2018; Zhang et al., 2017).”
BackgroundIntroduction to Ada programming
Price, D. (2000) · Prentice-Hall, Inc eBooks
Wu, Y., Ye, X., Zhu, Y., Liu, S., Song, J., Zhang, Y., Yuan, Q., Liu, F., Kong, D., & Zhao, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.586203
Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Prüß, A., Schmueck‐Henneresse, M., Volk, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22688654
Balke‐Want, H., Keerthi, V., Gkitsas-Long, N., Mancini, A. G., Kurgan, G., Fowler, C., Xu, P., Liu, X., Asano, K., Patel, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583513
Golubev, D. S., Komkov, D., Shepelev, M. V., Mazurov, D. V., & Kruglova, N. A. (2024) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738924010164
Rulleau, C., Aubin, M., Boudreau, G., Loiselle, A., Brasey, A., Smaani, A., Carli, C., Hardy, M., Busque, L., Perreault, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.01.691479
Self-citationBalke‐Want, H., Keerthi, V., Gkitsas-Long, N., Mancini, A. G., Kurgan, G., Fowler, C., Xu, P., Liu, X., Asano, K., Patel, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23583510
Četrti Doktorski dan Bi(o)znanosti?
Mravlje, J., & Starič, P. (2023) · Repository of the University of Ljubljana (University of Ljubljana)
Albers, J. J., Krackhardt, A., & München, T. U. (2024)
Afroza, D., Terada, K., Ito, K., Khan, M. A. J., Kondo, K., Yamasaki, K., Nagano, S., Masuda, K., Kawamoto, H., & Agata, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153623
CRISPR-Cas9-based strategies for enhanced targeted integration
Lacombe, L. (2024) · theses.fr (ABES) · doi:10.70675/9c9d279dz512az4b72z8322zea205cef9b67 · Cited by 1
HLA-G engineering reprograms CAR-T cells with an immune privilegePreprint
Xie, Y., Hong, S., & Xu, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.10.723228
“Even if we were able to make YP001 using plasmid as the HR donor very early on, we were biased in the beginning against plasmid due to its reported toxicity despite conflicting results ( 18 , 19 ).”
Generation and Characterization of CAR-T Cells
Ash, S., Attianese, G. M. P. G., Kosti, P., Semilietof, A., Stefanidis, E., Triboulet, M. M., & Irving, M. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5041-7_21
Reprogramming endogenous NK circuits by highly efficient nonviral genome editing
Huang, R., Phung, S. K., Sumstad, D., Weis, A., Kile, Q. M., Bendzick, L. E., Khaw, M. J., Vue, Y. Y., McKenna, D. H., Kennedy, P. R., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20260192
Toishigawa, K., Magoori, K., Sato, H., Edahiro, T., Ureshino, H., Shindo, T., Suzuki, R., Sakuma, T., Yamamoto, T., Okada, M., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102911
From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy
Aldahshan, H., Al-Hubaysh, A., Alrabiah, D. K., Alturki, M., Alkharji, R. R., Lin, S., Aldughaim, M. S., & Albugami, R. R. (2026) · Biomedicines · doi:10.3390/biomedicines14091925
“Nanoplasmid donors achieved 36.2–46.6% knock-in while preserving viability and expansion, resulting in approximately twofold and three-fold greater edited-cell yields than conventional plasmid and linear dsDNA donors, respectively [58].”
InfluentialChen, X., Qin, S., Yang, C., Xing, Z., Liu, C., Zhang, X., Wu, X., Li, X., Gong, Y., & Liu, Z. (2026) · Cell Proliferation · doi:10.1111/cpr.70285
T cell receptor-engineered T cells for hepatocellular carcinoma: next steps and future perspectives
Li, Z., Shu, J., Zhang, Q., Su, S., Zhou, J., Luan, Y., Xu, J., Gu, J., & Huang, X. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00075-1
“Ongoing process improvements, such as single-stranded DNA donor templates [52], nanoplasmids [53], intranuclear template shuttling [54], Cas9 RNP stabilization [54], and small-molecule cocktails [52], hold promise for further enhancing editing efficiency.”
From delivery to integration: CRISPR ‐mediated large insert gene editing in primary human T cells
Buttle, B., Verdon, D. J., & Sheppard, H. M. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70124
“44 Both the nanoplasmid and pUC57 plasmid HDRTs delivered improved insertion rates compared to dsDNA, possibly because circular DNA is more stable intracellularly than linear dsDNA.”
InfluentialMakvandi, P., Zamani, S., Fadaie, M., Najafi, M. B., Mofidfar, M., Dana, N., Avazzadeh, A., Mahmoudi, E., Deng, W., Huang, R., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.029
Metadata
- Authors
- Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S.
- Affiliations
- Genentech (US)
- Corresponding author
- Rutz, Sascha
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2022-04-22
- Volume
- 219
- Issue
- 5
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC9040063
- OpenAlex
- W4224255508
- Cited by
- 88
- References
- 59
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 23 · 2023: 21 · 2022: 5
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, human T cells, gene knock-in, gene knockout, transgene integration, Cas9 ribonucleoprotein, multiplex genome editing, adoptive T cell therapy, T cell engineering
- MeSH terms
- Gene Editing, DNA, Humans, Plasmids, T-Lymphocytes, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.